Givlaari®

Understanding Givlaari® 

Givlaari® (givosiran) is an RNA interference (RNAi) therapy used to treat Acute Hepatic Porphyria (AHP) in adults. It works by reducing the production of toxic intermediates in the liver that contribute to the severe symptoms of AHP, offering a targeted approach to managing this rare metabolic disorder.

How Givlaari® Works:

• Inhibits aminolevulinic acid synthase 1 (ALAS1) to reduce the buildup of neurotoxic intermediates.
• Helps prevent and reduce AHP attacks, improving patient outcomes.
• Provides a long-term therapeutic option for individuals living with AHP.

FDA Approval:

• Givlaari® (givosiran): Approved on November 20, 2019, for the treatment of AHP in adults.

For more information, please visit the Givlaari® patient website and speak with your healthcare provider to determine if Givlaari® is the right treatment option for you.